The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
This partnership now has the potential to develop research leading to cancer therapies which could save lives.
Professor Ugur Sahin, Chief Executive Officer and co-founder of BioNTech said:
The UK successfully delivered COVID-19 vaccines so quickly because the National Health Service, academia, the regulator and the private sector worked together in an exemplary way.
This agreement is a result of the lessons learnt from the COVID-19 pandemic. Drug development can be accelerated without cutting corners if everyone works seamlessly together towards the same goal. Today’s agreement shows we are committed to do the same for cancer patients.
Our goal is to accelerate the development of immunotherapies and vaccines using technologies we have been researching for over 20 years. The collaboration will cover various cancer types
Given the fact PYC were working with Camcer Research UK and also NHS Portsmouth and other leading UK organisations there must be a good chance they will come to PYC for advice and expertise
https://www.gov.uk/government/news/new-partnership-to-boost-research-into-vaccines-for-cancer
Government website
Secretary of State for Health and Social Care Steve Barclay to sign memorandum of understanding with BioNTech SE today to bring innovative vaccine research to England with the potential to transform outcomes for cancer patientsThe collaboration will aim to deliver 10,000 personalised therapies to UK patients by 2030 through a new research and development hub creating jobs and strengthening the UK’s position as a leader in global life sciencesThe new partnership will help accelerate clinical trials of personalised immunotherapies for cancer and infectious disease vaccines
Trials into vaccines for cancer and wider diseases will accelerate after the government reached a historic agreement with a leading biopharmaceutical firm to bring revolutionary research to England.
A memorandum of understanding will be signed today by Secretary of State for Health and Social Care Steve Barclay and the Germany-based company BioNTech, which previously developed a world-leading COVID-19 vaccine with Pfizer.
The agreement means cancer patients will get early access to trials exploring personalised mRNA therapies, like cancer vaccines. No 2 cancers are the same and mRNA vaccines will contain a genetic blueprint to stimulate the immune system to attack cancer cells.
Access to the trials will be through the Cancer Vaccine Launch Pad, which is being developed by NHS England and Genomics England.
The launch pad will help to rapidly identify large numbers of cancer patients who could be eligible for the trials and explore potential vaccines across multiple types of cancer. Trials for innovative treatments could start as early as autumn 2023.
The partnership will aim to help patients with early- and late-stage cancers. If successfully developed, the cancer vaccines could become part of standard care.
Let's hope Bicycle buy out Pyc then because all I am seeing is people saying lots of m and a activity so let's hope Pyc are part of it and put us out of our misery. Wishing the same for Sar and Val cause their sales staff are crappie too and their salaries denting cash flow!!!
I honestly believe Bicycle will end up being our biggest client and potential suitor
We’re pleased to announce that BT8009, Bicycle’s monotherapy in development for adult patients with previously treated locally advanced or metastatic #urothelialcancer, has been granted Fast Track Designation (FTD) by the
Portsmouth trial news next week, I wonder?
Twice lol
Not many shares in issue - moves rapid on proper volume
This hit 35p back a while
Anyways, some stellar buying today.Are we on the cusp of the transformational news many of us lth’s have hoped for for a number of years?
Agreed.
Most days lol without NT even with F A Trades haa
On HL it will not allow £1000 buys
Is anyone else having the dmaw problem please ?
Agree Homer.Small Bio been hammered by the markets in general last 9 months but Millen doesn’t help the Pyc cause with so few updates and non existent company promotion to a wider market ‘audience’ of where Pyc are and hope to be moving forward in the sector they operate in
I agree, but here we are at less than half that ! The markets are rarely fair.
7p is mickey mouse money for this tech.
13 months it has taken to get to over the monthly 8ema ,am i right ?
https://invst.ly/zz8gf
Wake me up at 7p
Life in the old dog still
Hiya L, that article is good for companies like Vaccitech, but unless they or other companies in this field use us for the modelling, then we wait for PARTNER study results.
UK is embarking on an ambitious plan to accelerate research into mRNA cancer vaccines, with German pharmaceutical company BioNTech.
Following the success of Covid vaccines using the same messenger-ribonucleic-acid technology, scientists now want to conduct more trials in cancer patients.
And they are hoping to provide this personalised type of treatment to about 10,000 patients by 2030.
Britain is the first nation to sign up to such a partnership.
BioNTech has several international cancer-vaccine trials in progress but says the UK is ideally placed as it has a great track record and infrastructure for medical research.
Thankyou both for those summaries
The trial was run at "The Christie" You never know he or his companies may have provided modelling support for the unnamed trial.
Correct King:
Provide data analysis and modelling support to CRUK Manchester Institute, Christie NHS and St. Mary's NHS. The work involves designing and analysing clinical trials in Oncology as well as working with non-trial, "real-world", data both in Oncology and other disease areas. This involves liasing with numerous medical and biological scientists as well as industrial collaborators running trials in Manchester.